Medical device manufacturers reportedly have agreed to pay higher fees to accelerate FDA reviews. The new agreement means over the next five years, device makers will pay about $595 million, up from $287 million. The FDA had failed to submit a pact to Congress by an earlier deadline, but agency spokeswoman Karen Riley said both parties are close to reaching a deal.

Full Story:

Related Summaries